Study limitations
UC
SOLID TUMOUR
As these data are from a small non-randomised, open-label study, they have some inherent limitations. Response and PFS were assessed in a small, heterogeneous group of patients with a range of advanced solid tumours with different levels of PD-L1 expression. The UC group, although small, did demonstrate activity; however, it could not be definitively concluded that this was superior to what could be expected for single-agent PD-1 or PD-L1 treatment, given the small sample size.